Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Download PDF Copy

Jun 29 2010

Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with advanced leukemias. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia.

"There is an enduring unmet need for effective new treatments for patients with refractory hematological malignancies," said Dr. Deborah Thomas, M.D., Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. "There is a strong preclinical rationale to evaluate TH-302 in this patient population and we are excited to be leading this innovative clinical trial."

Source:

Threshold Pharmaceuticals

Posted in: Drug Trial News | Medical Condition News

Tags: Acute Lymphoblastic Leukemia, Biotechnology, Bone, Bone Marrow, Cancer, Cell, Chronic Lymphocytic Leukemia, Clinical Trial, Doxorubicin, Gemcitabine, Hypoxia, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pharmaceuticals, Preclinical, Prostate Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Tumor

Comments (0)

Download PDF Copy

Suggested Reading

Resistant starch diet proves a game changer for weight loss and diabetes control

Resistant starch diet proves a game changer for weight loss and diabetes control

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Lancet Commission predicts sharp increase in global prostate cancer cases

Lancet Commission predicts sharp increase in global prostate cancer cases

The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients

The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients

Common HIV drugs linked to reduced Alzheimer's disease risk

Common HIV drugs linked to reduced Alzheimer's disease risk

Esketamine after childbirth cuts risk of postnatal depression by three-quarters

Esketamine after childbirth cuts risk of postnatal depression by three-quarters

Mediterranean diet and exercise reshape gut microbiome, aiding weight loss

Mediterranean diet and exercise reshape gut microbiome, aiding weight loss

Study highlights global fertility decline and its implications for the future

Study highlights global fertility decline and its implications for the future

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Cycles of a diet that mimics fasting can reduce signs of immune system aging, as well as insulin resistance and liver fat